[Efficiency of mexidol during perinatal encephalopathy in early age children].
We have investigated 200 patients 0-4 months of age (boys 110 and girls - 90), 120 of them under 1 month of age and 80 children from 1 to 4 months. The evaluation of the neurologic status of patients was performed 40-60 minutes after feeding in a relaxed condition. From the additional methods of the investigation of the nervous system, the most informative was the neurosonoscopy. We have divided patients into two groups according to the clinical syndromes: I gr. neuro-reflexion irritation syndrome (118 patients), II gr.--depression syndrome (82 patients). According to the treatment regimen patients also have been divided into two groups: the basic group (104 patients) with treatment only by mexydol (mexydol in a dose of 5 mg/kg and 0,3 ml in the form of injections twice a day. Injections were initiated at the acute stage of the disease) and the control group (96 patients) with no treatment. Efficiency of mexidol was estimated comparison of the findings in the basic and control groups based both on a clinical status and on the neurosonoscopic findings. Positive dynamics was observed in patients of the basic group. Verification of mexydol efficiency was performed by neurosonoscopic investigations. In a small portion of patients positive dynamics was not observed. These patients were from the age group from 3 to 4 months, which confirms that earlier and optimal treatment contribute to the prevention of severe neurological outcomes. It may be concluded that: 1. Mexydol acting on the pathogenetic mechanisms of perinatal encephalopathy, reduces reflexion irritation and depression syndromes both in neonatal and early age children. 2. Mexydol induces normalization of pathological neurosonoscopic patterns. 3. Mexydol with its wide pharmacological spectrum of action is an effective medicine in treatment of perinatal encephalopathy.
Natriashvili
G D
GD
Tbilisi State Medical University, Georgia.
Kapanadze
N B
NB
Natriashvili
S G
SG
D000975:Antioxidants / Q000627:therapeutic use*; D004453:Echoencephalography; D005260:Female; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000000981:diagnostic imaging / Q000188:drug therapy*; D007231:Infant, Newborn; D008297:Male; D010847:Picolines / Q000627:therapeutic use*
D000975:Antioxidants; D010847:Picolines; C070020:emoxypine succinate